Rezolute (NASDAQ:RZLT) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Rezolute (NASDAQ:RZLT) in a research note published on Monday,Benzinga reports. The firm currently has a $14.00 price target on the stock.

A number of other equities analysts have also recently weighed in on RZLT. Craig Hallum upgraded Rezolute to a “strong-buy” rating in a report on Tuesday, February 4th. Guggenheim reiterated a “buy” rating on shares of Rezolute in a report on Monday, February 10th. Finally, JMP Securities increased their price target on Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a report on Thursday, February 13th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $26.43.

Rezolute Stock Down 2.3 %

Shares of Rezolute stock opened at $3.76 on Monday. The firm has a market cap of $227.61 million, a PE ratio of -3.08 and a beta of 0.97. Rezolute has a 52 week low of $2.22 and a 52 week high of $6.19. The business’s fifty day simple moving average is $3.34 and its 200-day simple moving average is $4.44.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. As a group, equities analysts expect that Rezolute will post -0.93 earnings per share for the current year.

Insider Buying and Selling at Rezolute

In related news, Director Wladimir Hogenhuis purchased 10,000 shares of Rezolute stock in a transaction on Tuesday, February 18th. The shares were bought at an average price of $4.70 per share, with a total value of $47,000.00. Following the transaction, the director now directly owns 77,267 shares of the company’s stock, valued at approximately $363,154.90. This trade represents a 14.87 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Nevan C. Elam purchased 12,302 shares of Rezolute stock in a transaction on Thursday, March 27th. The stock was bought at an average cost of $2.85 per share, for a total transaction of $35,060.70. Following the transaction, the chief executive officer now directly owns 224,119 shares in the company, valued at $638,739.15. This represents a 5.81 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 39,060 shares of company stock valued at $130,694 in the last quarter. Corporate insiders own 18.39% of the company’s stock.

Institutional Investors Weigh In On Rezolute

Hedge funds have recently bought and sold shares of the stock. Jeppson Wealth Management LLC acquired a new stake in Rezolute in the 1st quarter valued at about $35,000. JPMorgan Chase & Co. purchased a new position in shares of Rezolute in the 3rd quarter valued at about $42,000. Alpine Global Management LLC purchased a new position in shares of Rezolute in the 4th quarter valued at about $54,000. Point72 Asia Singapore Pte. Ltd. increased its holdings in shares of Rezolute by 48.5% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company’s stock valued at $97,000 after acquiring an additional 6,470 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Rezolute by 65.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company’s stock valued at $112,000 after acquiring an additional 9,000 shares during the last quarter. Institutional investors and hedge funds own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.